Literature DB >> 22929759

Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis.

Stephen J Halpin1, Alexander C Ford.   

Abstract

OBJECTIVES: Symptoms compatible with irritable bowel syndrome (IBS) may co-exist in patients with inflammatory bowel disease (IBD), presenting a clinical dilemma for physicians. We conducted a systematic review and meta-analysis to examine this issue.
METHODS: MEDLINE, EMBASE, and EMBASE Classic were searched (through February 2012) to identify cross-sectional surveys or case-control studies reporting the prevalence of symptoms meeting diagnostic criteria for IBS in ≥50 unselected adult IBD patients. The number of individuals with symptoms meeting criteria for IBS was extracted for each study, and pooled prevalence and odds ratios (ORs), with 95% confidence intervals (CIs), were calculated.
RESULTS: The search identified 3,045 articles. Thirteen studies, containing 1,703 patients, were eligible. The pooled prevalence for IBS in all IBD patients was 39% (95% CI 30-48%), with an OR compared with controls of 4.89 (95% CI 3.43-6.98). In IBD patients in remission, the OR was 4.39 (95% CI 2.24-8.61). For IBD patients with active disease, the pooled prevalence of IBS was 44%, compared with 35% in those felt to be in remission (OR 3.89; 95% CI 2.71-5.59). The prevalence in patients with Crohn's disease (CD) was higher than in those with ulcerative colitis (UC; 46 vs. 36%, OR 1.62; 95% CI 1.21-2.18).
CONCLUSIONS: Symptoms compatible with IBS were significantly higher in patients with IBD compared with non-IBD controls, even among those felt to be in remission. IBS-type symptoms were also significantly more common in CD than in UC patients, and in those with active disease. Management strategies for IBD patients with symptoms suggestive of IBS are required.

Entities:  

Mesh:

Year:  2012        PMID: 22929759     DOI: 10.1038/ajg.2012.260

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  156 in total

Review 1.  Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice.

Authors:  Britt Christensen; David T Rubin
Journal:  Curr Gastroenterol Rep       Date:  2016-01

2.  The role of mucosal healing in the treatment of patients with inflammatory bowel disease.

Authors:  Byron P Vaughn; Sveta Shah; Adam S Cheifetz
Journal:  Curr Treat Options Gastroenterol       Date:  2014-03

Review 3.  Microbiota: a novel regulator of pain.

Authors:  Manon Defaye; Sandie Gervason; Christophe Altier; Jean-Yves Berthon; Denis Ardid; Edith Filaire; Frédéric Antonio Carvalho
Journal:  J Neural Transm (Vienna)       Date:  2019-09-24       Impact factor: 3.575

Review 4.  Antidepressants in inflammatory bowel disease.

Authors:  Antonina Mikocka-Walus; Alexander C Ford; Douglas A Drossman
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-02-18       Impact factor: 46.802

5.  Overlap Between Irritable Bowel Syndrome and Inflammatory Bowel Disease.

Authors:  Alexander C Ford
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-04

6.  Adherent-Invasive E. coli enhances colonic hypersensitivity and P2X receptors expression during post-infectious period.

Authors:  Amandine Lashermes; Ludivine Boudieu; Julie Barbier; Benoit Sion; Agathe Gelot; Nicolas Barnich; Denis Ardid; Frédéric Antonio Carvalho
Journal:  Gut Microbes       Date:  2017-10-04

Review 7.  Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide.

Authors:  Anke Heida; K T Park; Patrick F van Rheenen
Journal:  Inflamm Bowel Dis       Date:  2017-06       Impact factor: 5.325

Review 8.  Relationship between the exocrine and endocrine pancreas after acute pancreatitis.

Authors:  Stephanie L M Das; James I C Kennedy; Rinki Murphy; Anthony R J Phillips; John A Windsor; Maxim S Petrov
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 9.  Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology.

Authors:  Nicholas J Talley; Gerald Holtmann; Marjorie M Walker
Journal:  J Gastroenterol       Date:  2015-04-29       Impact factor: 7.527

Review 10.  Abnormal gut motility in inflammatory bowel disease: an update.

Authors:  G Bassotti; E Antonelli; V Villanacci; R Nascimbeni; M P Dore; G M Pes; G Maconi
Journal:  Tech Coloproctol       Date:  2020-02-15       Impact factor: 3.781

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.